Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture.

De Luca D, Vendittelli F, Trias J, Fraser H, Minucci A, Gentile L, Perez-Gil J, Conti G, Antonelli M, Capoluongo ED.

Curr Pharm Biotechnol. 2013;14(4):445-8.

PMID:
23590147
2.

Communication activity in stroke patients with aphasia.

Mazaux JM, Lagadec T, de Sèze MP, Zongo D, Asselineau J, Douce E, Trias J, Delair MF, Darrigrand B.

J Rehabil Med. 2013 Apr;45(4):341-6. doi: 10.2340/16501977-1122.

3.

Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury.

De Luca D, Minucci A, Trias J, Tripodi D, Conti G, Zuppi C, Capoluongo E; Study Group on Secretory Phospholipase in Pediatrics.

J Clin Pharmacol. 2012 May;52(5):729-37. doi: 10.1177/0091270011405498. Epub 2011 May 20.

PMID:
21602519
4.

Varespladib methyl in cardiovascular disease.

Rosenson RS, Fraser H, Trias J, Hislop C.

Expert Opin Investig Drugs. 2010 Oct;19(10):1245-55. doi: 10.1517/13543784.2010.517193. Review.

PMID:
20809869
5.

A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.

Leite JO, Vaishnav U, Puglisi M, Fraser H, Trias J, Fernandez ML.

BMC Cardiovasc Disord. 2009 Feb 17;9:7. doi: 10.1186/1471-2261-9-7.

6.

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.

Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J.

J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. doi: 10.1097/FJC.0b013e318195bfbc.

PMID:
19129734
7.

The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ.

J Lipid Res. 2009 Apr;50(4):623-9. doi: 10.1194/jlr.M800361-JLR200. Epub 2008 Nov 21.

8.

Novel antibacterial azetidine lincosamides.

O'Dowd H, Lewis JG, Trias J, Asano R, Blais J, Lopez SL, Park CK, Wu C, Wang W, Gordeev MF.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2645-8. doi: 10.1016/j.bmcl.2008.03.032. Epub 2008 Mar 14.

PMID:
18359228
9.

Neutrophil chemotaxis by pathogen-associated molecular patterns--formylated peptides are crucial but not the sole neutrophil attractants produced by Staphylococcus aureus.

Dürr MC, Kristian SA, Otto M, Matteoli G, Margolis PS, Trias J, van Kessel KP, van Strijp JA, Bohn E, Landmann R, Peschel A.

Cell Microbiol. 2006 Feb;8(2):207-17.

PMID:
16441432
10.

BanTeC: a software tool for management of corneal transplantation.

López-Alvarez P, Caballero F, Trias J, Cortés U, López-Navidad A.

Transplant Proc. 2005 Nov;37(9):4084-6.

PMID:
16386632
11.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii21-4.

PMID:
15750033
12.

Conformationally restricted analogs of deoxynegamycin.

Raju B, Anandan S, Gu S, Herradura P, O'Dowd H, Kim B, Gomez M, Hackbarth C, Wu C, Wang W, Yuan Z, White R, Trias J, Patel DV.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3103-7.

PMID:
15149653
13.

Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach.

Chen D, Hackbarth C, Ni ZJ, Wu C, Wang W, Jain R, He Y, Bracken K, Weidmann B, Patel DV, Trias J, White RJ, Yuan Z.

Antimicrob Agents Chemother. 2004 Jan;48(1):250-61.

14.

Alpha-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents.

Jain R, Sundram A, Lopez S, Neckermann G, Wu C, Hackbarth C, Chen D, Wang W, Ryder NS, Weidmann B, Patel D, Trias J, White R, Yuan Z.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4223-8. Erratum in: Bioorg Med Chem Lett. 2004 May 3;14(9):2373-4.

PMID:
14623006
15.

Novel oxazolidinone-quinolone hybrid antimicrobials.

Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Gomez M, Trias J, Morin SE, Zurenko GE, Parker CN, Evans JM, White RJ, Patel DV.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4213-6.

PMID:
14623004
16.

New antibacterial tetrahydro-4(2H)-thiopyran and thiomorpholine S-oxide and S,S-dioxide phenyloxazolidinones.

Singh U, Raju B, Lam S, Zhou J, Gadwood RC, Ford CW, Zurenko GE, Schaadt RD, Morin SE, Adams WJ, Friis JM, Courtney M, Palandra J, Hackbarth CJ, Lopez S, Wu C, Mortell KH, Trias J, Yuan Z, Patel DV, Gordeev MF.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4209-12.

PMID:
14623003
17.

Targeting metalloenzymes: a strategy that works.

White RJ, Margolis PS, Trias J, Yuan Z.

Curr Opin Pharmacol. 2003 Oct;3(5):502-7. Review.

PMID:
14559095
18.

Combinatorial modification of natural products: synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: A-ring modifications.

Clough J, Chen S, Gordon EM, Hackbarth C, Lam S, Trias J, White RJ, Candiani G, Donadio S, Romanò G, Ciabatti R, Jacobs JW.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3409-14.

PMID:
14505638
19.
20.

N- and C-terminal modifications of negamycin.

Raju B, Mortell K, Anandan S, O'Dowd H, Gao H, Gomez M, Hackbarth C, Wu C, Wang W, Yuan Z, White R, Trias J, Patel DV.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2413-8.

PMID:
12824046
21.

Identification of potent and broad-spectrum antibiotics from SAR studies of a synthetic vancomycin analogue.

Ahrendt KA, Olsen JA, Wakao M, Trias J, Ellman JA.

Bioorg Med Chem Lett. 2003 May 19;13(10):1683-6.

PMID:
12729641
22.

N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity.

Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold JB, Cramer JA, Margolis PS, Wang W, Koehn J, Wu C, Lopez S, Withers G 3rd, Gu H, Dunn E, Kulathila R, Pan SH, Porter WL, Jacobs J, Trias J, Patel DV, Weidmann B, White RJ, Yuan Z.

Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64.

23.

The role of combichem in antibiotic discovery.

Trias J.

Curr Opin Microbiol. 2001 Oct;4(5):520-5. Review.

PMID:
11587927
24.

Perspectives on genomics and antibiotic discovery.

Trias J.

Curr Opin Investig Drugs. 2001 Jun;2(6):742-4. Review. No abstract available.

PMID:
11572650
25.

Deformylase as a novel antibacterial target.

Yuan Z, Trias J, White RJ.

Drug Discov Today. 2001 Sep 15;6(18):954-961.

PMID:
11546610
26.

Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB.

Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J.

Antimicrob Agents Chemother. 2001 Sep;45(9):2432-5.

27.

Mining bacterial cell wall biosynthesis with new tools: multitarget screens.

Trias J, Yuan Z.

Drug Resist Updat. 1999 Dec;2(6):358-362.

PMID:
11498351
28.

A fluorescence-based homogeneous assay for measuring activity of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase.

Wang W, Maniar M, Jain R, Jacobs J, Trias J, Yuan Z.

Anal Biochem. 2001 Mar;290(2):338-46.

PMID:
11237337
29.

Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene.

Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J.

Antimicrob Agents Chemother. 2000 Jul;44(7):1825-31.

30.

Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor.

Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z.

Biochemistry. 2000 Feb 15;39(6):1256-62.

PMID:
10684604
32.

Innovative approaches to novel antibacterial drug discovery.

Trias J, Gordon EM.

Curr Opin Biotechnol. 1997 Dec;8(6):757-62. Review.

PMID:
9425668
33.

Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Dib C, Trias J, Jarlier V.

Eur J Clin Microbiol Infect Dis. 1995 Nov;14(11):979-86.

PMID:
8654449
34.

Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.

Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V.

Antimicrob Agents Chemother. 1995 Oct;39(10):2248-52.

35.

Search for protein cross-reacting with OprD antibodies in Pseudomonas spp. and related species.

Dib C, Trias J, Jarlier V.

J Antimicrob Chemother. 1994 Dec;34(6):1077-80. No abstract available.

PMID:
7730227
36.

Permeability of the cell wall of Mycobacterium smegmatis.

Trias J, Benz R.

Mol Microbiol. 1994 Oct;14(2):283-90.

PMID:
7830572
37.

Transcription and expression analysis, using lacZ and phoA gene fusions, of Mycobacterium fortuitum beta-lactamase genes cloned from a natural isolate and a high-level beta-lactamase producer.

Timm J, Perilli MG, Duez C, Trias J, Orefici G, Fattorini L, Amicosante G, Oratore A, Joris B, Frère JM, et al.

Mol Microbiol. 1994 May;12(3):491-504.

39.

Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane.

Fukuoka T, Ohya S, Narita T, Katsuta M, Iijima M, Masuda N, Yasuda H, Trias J, Nikaido H.

Antimicrob Agents Chemother. 1993 Feb;37(2):322-7.

40.

Porins in the cell wall of mycobacteria.

Trias J, Jarlier V, Benz R.

Science. 1992 Nov 27;258(5087):1479-81.

PMID:
1279810
44.

Brown pigmentation in Serratia marcescens cultures associated with tyrosine metabolism.

Trias J, Viñas M, Guinea J, Lorèn JG.

Can J Microbiol. 1989 Nov;35(11):1037-42.

PMID:
2692797
45.

Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa.

Trias J, Dufresne J, Levesque RC, Nikaido H.

Antimicrob Agents Chemother. 1989 Aug;33(8):1202-6.

46.

Induction of Yellow Pigmentation in Serratia marcescens.

Trias J, Viñas M, Guinea J, Lorén JG.

Appl Environ Microbiol. 1988 Dec;54(12):3138-41.

47.

Specificity of the glucose channel formed by protein D1 of Pseudomonas aeruginosa.

Trias J, Rosenberg EY, Nikaido H.

Biochim Biophys Acta. 1988 Mar 3;938(3):493-6.

PMID:
2450582
48.

Isolation from urine of two Serratia marcescens strains excreting a diffusible yellow pigment.

Trias J, Viñas M, Guinea J, Lorén JG.

J Gen Microbiol. 1987 Mar;133(3):773-7.

PMID:
3309170
49.

[XY gonadal dysgenesis with female phenotype (author's transpl)].

Trias JV, Martínez FB.

Reproduccion. 1975 Apr-Jun;2(2):111-21. Spanish.

PMID:
1213239

Supplemental Content

Support Center